Clinical trial
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
NCT00006368 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00006368 |
|---|---|
| Title | Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer |
| Official title | A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome |
| Intervention type | Radiation |
| Interventions | yttrium Y 90-edotreotide |
| Enrollment | 60 |
| Start date | Jan 1, 1998 |
| Primary completion | Nov 1, 2003 |
| Completion | Nov 1, 2003 |
| First posted | Apr 2, 2004 |
| Last update posted | May 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: